Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
179M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
49.5M
-
Shares change
-
+3.39M
-
Total reported value, excl. options
-
$472M
-
Value change
-
+$28.5M
-
Put/Call ratio
-
0.1
-
Number of buys
-
45
-
Number of sells
-
-19
-
Price
-
$9.54
Significant Holders of Prime Medicine, Inc. - Common Stock, $0.00001 par value (PRME) as of Q3 2023
89 filings reported holding PRME - Prime Medicine, Inc. - Common Stock, $0.00001 par value as of Q3 2023.
Prime Medicine, Inc. - Common Stock, $0.00001 par value (PRME) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.5M shares
of 179M outstanding shares and own 27.71% of the company stock.
Largest 10 shareholders include Alphabet Inc. (11.9M shares), VANGUARD GROUP INC (3.95M shares), FMR LLC (3.92M shares), Nikko Asset Management Americas, Inc. (3.63M shares), Sumitomo Mitsui Trust Holdings, Inc. (3.63M shares), BlackRock Inc. (3.33M shares), ARK Investment Management LLC (2.62M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.17M shares), FIL Ltd (1.81M shares), and MWG Management Ltd. (1.79M shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.